Soleno Therapeutics (SLNO) Financials

Soleno Therapeutics Inc (SLNO) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's financials show a steady growth in revenue and a significant increase in gross profit over the past year. According to the income statement, Soleno Therapeutics Inc reported a total revenue of $10 million, with a gross profit of $7 million in the last fiscal year.

The company's EBIT (earnings before interest and taxes) stood at $2 million, reflecting a positive operating income. Soleno Therapeutics Inc's EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to $3 million, indicating a strong financial performance.

Soleno Therapeutics Inc's net income from stockholders reached $1 million, demonstrating profitability. The company's balance sheet highlights a healthy stockholders' equity of $4 million and total assets of $15 million. The total debt and total liabilities stood at $2 million and $9 million, respectively.

Soleno Therapeutics Inc had cash equivalents of $3 million, ensuring liquidity for its operations. The company's net debt amounted to $1 million, indicating a manageable level of leverage.

In terms of cash flow, Soleno Therapeutics Inc generated a positive operating cash flow of $2 million, reflecting its ability to generate cash from its core operations. The financing cash flow was $1 million, indicating the company's ability to raise capital for its growth initiatives.

The investing cash flow stood at -$1 million, suggesting that the company made investments in its long-term growth and development. Soleno Therapeutics Inc's free cash flow was $1 million, indicating its ability to generate cash after meeting its capital expenditure requirements.

Overall, Soleno Therapeutics Inc's financials demonstrate a strong and sustainable financial position, with steady revenue growth, profitability, and healthy liquidity. The company's focus on the development of novel therapeutics for rare diseases positions it well for future success.